Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test Article A Clear all
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

NCT01502020
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, 3.75%, Vehicle Cream
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)

NCT03012347
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, BullFrog Gel Sunscreen Land Sport SPF-50
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

NCT00384358
View directory record Official record
Conditions
Fractures
Interventions
rhBMP-2/CPM, surgical intervention alone
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • New Haven, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Novel Cooling Vest to Protect Persons With SCI From Hyperthermia

NCT05441449
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Cooling Vest
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 68 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 13, 2026, 10:02 AM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18850 - Human Photoallergy Test

NCT02751463
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreening Sport Spray Rest (BAY987519), Untreated skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

NCT00195351
View directory record Official record
Conditions
Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions
tigecycline, ceftriaxone sodium + metronidazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
46
States / cities
Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 13, 2026, 10:02 AM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT07538583
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
4 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Fremont, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"

NCT01677195
View directory record Official record
Conditions
Dietary Carcinogenesis
Interventions
ACCS100, Placebo
Drug
Lead sponsor
Texas Enterosorbents Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

NCT05363449
View directory record Official record
Conditions
Tinea Cruris, Tinea Pedis
Interventions
UHE-103 Cream, Naftin (naftifine hydrochloride) Cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
San Diego, California • Thousand Oaks, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 13, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury

NCT01433159
View directory record Official record
Conditions
Pressure Ulcers, Spinal Cord Injury
Interventions
HP011-101 (Xenaderm Ointment), Standard Care
Drug
Lead sponsor
Healthpoint
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Jose, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Sep 13, 2026, 10:02 AM EDT
Not listed Not applicable Interventional

Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)

NCT02363842
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Skin IQ™ MCM Coverlet, Pressure redistribution surface
Device · Other
Lead sponsor
Arjohuntleigh
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

China Obstetrics and Gynecology Journal Club

NCT01844609
View directory record Official record
Conditions
Language Disorders
Interventions
Self Study Journal Club, Intensive Journal Club
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitization Study of ATx201 in Healthy Volunteers

NCT03375957
View directory record Official record
Conditions
Sensitivity, Contact
Interventions
ATx201, ATx201 Placebo Gel
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Sep 13, 2026, 10:02 AM EDT
Not listed Phase 1Phase 2 Interventional

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

NCT05458544
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
[177Lu]Ludotadipep 3.7 GBq
Drug
Lead sponsor
FutureChem
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste

NCT02992314
View directory record Official record
Conditions
Medication Associated Metallic Taste , Dysgeusia
Interventions
Metaqil™ Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels

NCT04821557
View directory record Official record
Conditions
Protein Metabolism
Interventions
Protease + Protein, Placebo + Protein
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

NCT00380900
View directory record Official record
Conditions
Healthy Subjects, Osteoarthritis
Interventions
AGG-523
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

NCT04510675
View directory record Official record
Conditions
Erythema, Sensitisation
Interventions
Test Article, Negative Control
Device · Other
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 13, 2026, 10:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Collect Calibration & Performance Data of the KBS Systems 1.0 Non-Invasive Glucose Monitoring Device

NCT03607435
View directory record Official record
Conditions
Diabetes
Interventions
Spectroscopy for Analyte Quantification
Device
Lead sponsor
Florida Hospital Tampa Bay Division
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 13, 2026, 10:02 AM EDT
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
View directory record Official record
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 13, 2026, 10:02 AM EDT
Recruiting Phase 2Phase 3 Interventional

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

NCT06953466
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003, 4% Lotion
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 13, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 13, 2026, 10:02 AM EDT